Chamath Palihapitiya (Scott Eells/Bloomberg via Getty Images)

A dry-pow­der lung dis­ease drug and next-gen an­tibi­otics: Two biotechs and an $880M slate of SPACs land on Wall Street with big ideas

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

An­oth­er cou­ple of biotech com­pa­nies and four SPACs are hit­ting Wall Street, adding to yet an­oth­er busy week for IPOs.

Aerovate Ther­a­peu­tics is tak­ing its dry-pow­der ver­sion of a pop­u­lar can­cer drug pub­lic, rak­ing in more than $121 mil­lion. Acurx Phar­ma­ceu­ti­cals snared a mod­est $14.8 mil­lion raise to tack­le the loom­ing threat of an­timi­cro­bial re­sis­tance. And Chamath Pal­i­hapi­tiya, the so-called ‘SPAC King,’ has round­ed up $880 mil­lion across four blank check com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.